ABIVAX Société Anonyme (NASDAQ:ABVX) Earns “Equal Weight” Rating from Morgan Stanley

Morgan Stanley reissued their equal weight rating on shares of ABIVAX Société Anonyme (NASDAQ:ABVX) in a research note issued to investors on Thursday morning, MarketBeat Ratings reports. Morgan Stanley currently has a $12.00 target price on the stock.

Several other analysts have also weighed in on the company. JMP Securities reissued a “market outperform” rating and set a $33.00 price objective on shares of ABIVAX Société Anonyme in a report on Friday, January 10th. Citizens Jmp raised ABIVAX Société Anonyme to a “strong-buy” rating in a report on Wednesday, December 4th. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $38.00.

ABIVAX Société Anonyme Stock Up 4.5 %

ABVX opened at $7.38 on Thursday. The stock’s 50 day moving average price is $6.73 and its two-hundred day moving average price is $8.52. ABIVAX Société Anonyme has a 12-month low of $5.50 and a 12-month high of $16.63.

Institutional Trading of ABIVAX Société Anonyme

Several institutional investors have recently bought and sold shares of the stock. Two Sigma Investments LP acquired a new stake in ABIVAX Société Anonyme in the 4th quarter valued at $144,000. Stonepine Capital Management LLC acquired a new stake in ABIVAX Société Anonyme in the 4th quarter valued at $110,000. Shay Capital LLC acquired a new stake in ABIVAX Société Anonyme in the 4th quarter valued at $366,000. Millennium Management LLC boosted its stake in ABIVAX Société Anonyme by 44.2% in the 4th quarter. Millennium Management LLC now owns 931,179 shares of the company’s stock valued at $6,816,000 after buying an additional 285,542 shares in the last quarter. Finally, Citadel Advisors LLC boosted its stake in ABIVAX Société Anonyme by 83.5% in the 4th quarter. Citadel Advisors LLC now owns 855,676 shares of the company’s stock valued at $6,264,000 after buying an additional 389,247 shares in the last quarter. Institutional investors and hedge funds own 47.91% of the company’s stock.

ABIVAX Société Anonyme Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.